D. E. Shaw & Co., Inc. Curis Inc Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $327,291 - $1.12 Million	-460,974 Reduced 31.24%	1,014,833 $999,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $3.08 Million - $6.84 Million	1,333,484 Added 936.94%	1,475,807 $3.51 Million
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $398,946 - $725,276	89,651 Added 170.21%	142,323 $677,000
Q3 2021 Nov 15, 2021	SELL	$6.94 - $8.85 $70,600 - $90,031	-10,173 Reduced 16.19%	52,672 $412,000
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $468,195 - $1.02 Million	62,845 New	62,845 $507,000
Q1 2019 May 15, 2019	SELL	$0.78 - $2.01 $10,987 - $28,312	-14,086 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$0.62 - $2.25 $29,030 - $105,351	-46,823 Reduced 76.87%	14,086 $10,000
Q3 2018 Nov 14, 2018	SELL	$1.38 - $1.94 $88,860 - $124,920	-64,392 Reduced 51.39%	60,909 $108,000
Q2 2018 Aug 14, 2018	BUY	$1.73 - $3.35 $216,770 - $419,758	125,301 New	125,301 $217,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.